207 related articles for article (PubMed ID: 9145875)
1. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89.
Tisdale M; Alnadaf T; Cousens D
Antimicrob Agents Chemother; 1997 May; 41(5):1094-8. PubMed ID: 9145875
[TBL] [Abstract][Full Text] [Related]
2. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
Tisdale M; Kemp SD; Parry NR; Larder BA
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
[TBL] [Abstract][Full Text] [Related]
3. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA
AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801
[TBL] [Abstract][Full Text] [Related]
4. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity.
Daluge SM; Good SS; Faletto MB; Miller WH; St Clair MH; Boone LR; Tisdale M; Parry NR; Reardon JE; Dornsife RE; Averett DR; Krenitsky TA
Antimicrob Agents Chemother; 1997 May; 41(5):1082-93. PubMed ID: 9145874
[TBL] [Abstract][Full Text] [Related]
5. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance.
Larder BA; Bloor S; Kemp SD; Hertogs K; Desmet RL; Miller V; Sturmer M; Staszewski S; Ren J; Stammers DK; Stuart DI; Pauwels R
Antimicrob Agents Chemother; 1999 Aug; 43(8):1961-7. PubMed ID: 10428920
[TBL] [Abstract][Full Text] [Related]
6. Anti-HIV type 1 activity of 3'-fluoro-3'-deoxythymidine for several different multidrug-resistant mutants.
Kim EY; Vrang L; Oberg B; Merigan TC
AIDS Res Hum Retroviruses; 2001 Mar; 17(5):401-7. PubMed ID: 11282008
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants.
Gu Z; Wainberg MA; Nguyen-Ba N; L'Heureux L; de Muys JM; Bowlin TL; Rando RF
Antimicrob Agents Chemother; 1999 Oct; 43(10):2376-82. PubMed ID: 10508010
[TBL] [Abstract][Full Text] [Related]
8. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine.
Bazmi HZ; Hammond JL; Cavalcanti SC; Chu CK; Schinazi RF; Mellors JW
Antimicrob Agents Chemother; 2000 Jul; 44(7):1783-8. PubMed ID: 10858331
[TBL] [Abstract][Full Text] [Related]
9. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine.
Hooker DJ; Tachedjian G; Solomon AE; Gurusinghe AD; Land S; Birch C; Anderson JL; Roy BM; Arnold E; Deacon NJ
J Virol; 1996 Nov; 70(11):8010-8. PubMed ID: 8892925
[TBL] [Abstract][Full Text] [Related]
10. The impact of multidideoxynucleoside resistance-conferring mutations in human immunodeficiency virus type 1 reverse transcriptase on polymerase fidelity and error specificity.
Rezende LF; Curr K; Ueno T; Mitsuya H; Prasad VR
J Virol; 1998 Apr; 72(4):2890-5. PubMed ID: 9525609
[TBL] [Abstract][Full Text] [Related]
11. The base component of 3'-azido-2',3'-dideoxynucleosides influences resistance mutations selected in HIV-1 reverse transcriptase.
Meteer JD; Koontz D; Asif G; Zhang HW; Detorio M; Solomon S; Coats SJ; Sluis-Cremer N; Schinazi RF; Mellors JW
Antimicrob Agents Chemother; 2011 Aug; 55(8):3758-64. PubMed ID: 21646480
[TBL] [Abstract][Full Text] [Related]
12. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
[TBL] [Abstract][Full Text] [Related]
13. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.
Boyer PL; Imamichi T; Sarafianos SG; Arnold E; Hughes SH
J Virol; 2004 Sep; 78(18):9987-97. PubMed ID: 15331732
[TBL] [Abstract][Full Text] [Related]
14. The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.
Miranda LR; Götte M; Liang F; Kuritzkes DR
Antimicrob Agents Chemother; 2005 Jul; 49(7):2648-56. PubMed ID: 15980332
[TBL] [Abstract][Full Text] [Related]
15. High-level resistance to 3'-azido-3'-deoxythimidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1.
Imamichi T; Sinha T; Imamichi H; Zhang YM; Metcalf JA; Falloon J; Lane HC
J Virol; 2000 Jan; 74(2):1023-8. PubMed ID: 10623768
[TBL] [Abstract][Full Text] [Related]
16. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine.
Brehm JH; Koontz D; Meteer JD; Pathak V; Sluis-Cremer N; Mellors JW
J Virol; 2007 Aug; 81(15):7852-9. PubMed ID: 17507476
[TBL] [Abstract][Full Text] [Related]
17. Identification of insertion mutations in HIV-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors.
Sugiura W; Matsuda M; Matsuda Z; Abumi H; Okano A; Oishi T; Moriya K; Yamamoto Y; Fukutake K; Mimaya J; Ajisawa A; Taki M; Yamada K; Nagai Y
J Hum Virol; 1999; 2(3):146-53. PubMed ID: 10413366
[TBL] [Abstract][Full Text] [Related]
18. Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision.
Boyer PL; Sarafianos SG; Arnold E; Hughes SH
J Virol; 2002 Sep; 76(18):9143-51. PubMed ID: 12186898
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.
Sluis-Cremer N; Sheen CW; Zelina S; Torres PS; Parikh UM; Mellors JW
Antimicrob Agents Chemother; 2007 Jan; 51(1):48-53. PubMed ID: 17088490
[TBL] [Abstract][Full Text] [Related]
20. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
